Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis

Journal of Trauma and Acute Care Surgery

Volumn 72, Issue 5, 2012, Pages 1150-1157

  Ogawa, Yoshihito ^a,b   Yamakawa, Kazuma ^b   Ogura, Hiroshi ^b   Kiguchi, Takeyuki ^a   Mohri, Tomoyoshi ^a   Nakamori, Yasushi ^a   Kuwagata, Yasuyuki ^b   Shimazu, Takeshi ^b   Hamasaki, Toshimitsu ^b   Fujimi, Satoshi ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Activated protein C; Acute lung injury; Acute respiratory distress syndrome; Disseminated intravascular coagulation; Lung injury score

Indexed keywords

RECOMBINANT THROMBOMODULIN; STEROID;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; SCORING SYSTEM; SEPSIS; VENTILATOR;

AGED; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT PROTEINS; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE; THROMBOMODULIN;

EID: 84864558977     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e3182516ab5     Document Type: Article

References (21)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348: 1546-1554.
2. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28:108-121.
3. Perl M, Lomas-Neira J, Venet F, Chung CS, Ayala A. Pathogenesis of indirect (secondary) acute lung injury. Expert Rev Respir Med. 2011;5: 115-126.
4. Ogura H, Gando S, Iba T, et al. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock. 2007;28:411-417.
5. Guitton C, Cottereau A, Gerard N, et al. Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-kappaB, and ERK1/2 MAP kinases. Am J Physiol Cell Physiol. 2011;300:C833-C842.
6. Hofstra JJ, Juffermans NP, Schultz MJ, Zweers MM. Pulmonary coagulopathy as a new target in lung injury-a review of available pre-clinical models. Curr Med Chem. 2008;15:588-595.
7. Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med. 2003;31:S329-S336.
8. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008;178:618-623.
9. Yamakawa K, Fujimi S, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: A historical control study. Crit Care. 2011;15:R123.
10. Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Crit Care Med. 2006;34:625-631.
11. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873.
12. Siddiki H, Kojicic M, Li G, et al. Bedside quantification of deadspace fraction using routine clinical data in patients with acute lung injury: Secondary analysis of two prospective trials. Crit Care. 2010;14:R141.
13. Wang YX, Wu C, Vincelette J, et al. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin. Thromb Haemost. 2006;96:317-324.
14. Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T. In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock. 2010;33:282-288.
15. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41.
16. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: Subanalysis from the phase 3 trial. Shock. 2011; 35:349-354.
17. Del Sorbo L, Slutsky AS. Acute respiratory distress syndrome and multiple organ failure. Curr Opin Crit Care. 2011;17:1-6.
18. Finigan JH. The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res. 2009;77:35-38.
19. Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol. 1996;271:L470-L475.
20. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003;31:834-840.
21. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754-1758.